Slide 1: Uscom (UCM) – Global Medical Devices: Revenue growth
Uscom (UCM) – Global Medical Devices For personal use only Revenue growth May 2016 Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Uscom Executive Chairman/CEO The Measure of Life
Slide 2: Disclaimer
Disclaimer For personal use only This presenta,on is intended to provide a general outline only and is not intended to be a defini,ve statement on the subject ma9er. The informa,on in this presenta,on, whether wri9en or verbal, has been prepared without taking into account the commercial, financial or
Slide 3: Uscom
Uscom For personal use only “A rapidly growing Australian medical device company with world leading products and a strategic global corporate vision…” 3 Uscom – Devices the experts use
Slide 4: For personal use only
For personal use only 4
Slide 5: Uscom Recognition
Uscom Recognition For personal use only Company of the Year, 2014 Johnson & Johnson Innova@on Industry Excellence Awards “A milestone driven, rapidly growing global medical device company, with real products, real revenue, real growth and an aggressive growth strategy” 5 Uscom – Devices the experts
Slide 6: Business Background
Business Background For personal use only § Premium noninvasive cardiovascular and pulmonary monitoring devices § Addressing the growing threat of superbugs, heart failure, hypertension and asthma § Validated, clinically accepted, cost and life saving devices with cri,cal applica,ons § Aggressiv
Slide 7: Strategic growth
Strategic growth For personal use only Uscom Pulsecor Thor Uscom Limited Limited Kft Limited $50m $50m $50m 2016 2010 2013 2015 Rapidly strengthening balance sheet Acquisi<ve, strategic and diversified en<ty Acquired and integrated Pulsecor (2013) and Thor (2015) Debt free acquisi<ons – scrip, raisin
Slide 8: Products and Market
Products and Market For personal use only Mul@ple high fidelity noninvasive digital medical devices Fluid, Sepsis Hypertension & COPD & Heart Failure Vascular Health & Asthma § US 1.3bn market * § US 1.7bn market * § US 400m market * § CAGR of 7.6% * § CAGR of 11.5% * § CAGR of 6.5% * § CE, FD
Slide 9: Products - USCOM 1A
Products - USCOM 1A For personal use only Heart failure, hypertension, sepsis, fluid Non invasive, accurate, compact, platform technology Accurate cardiac output Works with all other hospital equipment Cardiac stroke volume Intuitive touch screen Systemic vascular Real time data resistance Platform
Slide 10: Products - USCOM 1A: pediatric sepsis
Products - USCOM 1A For personal use only USCOM use in pediatric sepsis -46% Mortality! Lives Saved! Septic Shock Mortality in King Chulalongkorn Memorial Hospital – Uscom use began in 2013. Thongnual C, Hantragool S, Samransamriatkit R. Efficacy of non-invasive cardiac monitoring (Ultrasonic Cardia
Slide 11: Products - Uscom BP+
Products - Uscom BP+ For personal use only Hypertension, heart failure and vascular disease Central Blood Pressure and Pulse Wave Analysis The new standard for hypertension • FDA, CE Mark, TGA approvals • Home or clinic • Supra-systolic • PPW Analysis Oscollometry • Results in • Reliable and 30 seco
Slide 12: Products - Uscom SpiroSonic
Products - Uscom SpiroSonic For personal use only Asthma, COPD, Occupational Lung Disease and drug compliance monitoring • High fidelity digital ultrasonic spirometry • Multi-path ultrasonic sensing • FDA, CE, and TGA approvals • Reliable and accurate • Auto calibration • Research, home and clinic •
Slide 13: Future - Big Data
Future - Big Data For personal use only Big data needs high quality sensors Uscom specialises in high quality non-invasive sensors • Software analytics • Telemetric signals • Cloud based processing/diagnosis • Personalised clinical advice • Medication and dosage • Serial monitoring • Multiple measur
Slide 14: De-Risked Technology
De-Risked Technology For personal use only Featured in 500+ peer reviewed publications and presentations Sepsis, Heart failure, Hypertension, Fluid management, Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Emergency transport, Anesthesia, Liver transplantation, ICU, Pre-eclampsi
Slide 15: Global: Continued Global Growth
Global 1. Uscom Aus Continued Global Growth 2. 3. Uscom UK Uscom Budapest For personal use only 4. Uscom USA 2• •• •••• • •• •• 3 • • • •• • • ••• • 4 •• • •• • • • • • •• Key Markets 1. AsiaPAC – 65% 2/3. Europe – 27% • • • 1 4. Nth America – 8% US Focus FY 2017 Stephen Wilson – Former VP Corporate
Slide 16: Global Profile - Vietnam Health
Global Profile - Vietnam Health For personal use only Pham Thi Lan Anh Head of Medical Prevention Department Pham Quang Cu Nguyen Tien Dan Vice Director General Head of Dept of Health Pham Quoc Cuong General Directorate of Techniques & Department of Health – General Directorate Vice Director of 19-8
Slide 17: China Growth
China Growth David He joins UCM Board For personal use only Formerly J&J China China Health Expenditure as % of GDP 7.9 China Health Spend (USD) GDP=12,000,000,000,000 6.5 Health=5.4%=648,000,000,000 5.1 5.0 5.1 5.4 Objec,ve=12%=1,400,000,000,000 4.8 4.8 4.7 4.7 4.6 4.4 4.6 4.6 Increase=6.6%=792,000
Slide 18: New US Products
New US Products For personal use only For launch early FY 2017 18 Uscom – Devices the experts use
Slide 19: US CPT Codes
US CPT Codes For personal use only US Reimbursement Codes for Uscom Technologies Uscom CPT Descriptor Value Products Code (USD) BP+ 93050 Central BP and PWA $17.91 SpiroSonic 94010 Spirometry $36 94060 Pre and post bronchodilator administration, spirometry $61 94375 Respiratory flow volume loop $40
Slide 20: Growth - UCM
Growth - UCM For personal use only A blue sky story with de-‐risked operaWons UCM Revenue and Income UCM Distribution Agreements $2,500,000 40 38 $2,039,426 $2,000,000 35 30 27 $1,500,000 $1,377,716 25 $1,010,942 20 $1,000,000 15 12 10 $500,000 5 $0 0 2013 2014 2015 2013 2014 2015 Current revenue o
Slide 21: Growth - UCM: Quarterly Sales Revenue
Growth - UCM For personal use only UCM Quarterly Sales Revenue 750,000 650,000 550,000 450,000 $ 350,000 250,000 150,000 50,000 (50,000) Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16 Current revenue only from USCOM 1A 21 BP+ and SpiroSonic revenue in FY 2017
Slide 22: Revenue Targets
Revenue Targets For personal use only Total Revenue SpiroSonic – FY 2017 20,000,000 18,000,000 16,000,000 BP+ -‐ FY 2017 14,000,000 12,000,000 SpiroSonic $ 10,000,000 BP+ USCOM 8,000,000 USCOM 6,000,000 4,000,000 2,000,000 0 2015 2016* 2017* 2018* 2019* 2020* 22 $20m revenue by 2020 = 5 year CAGR o
Slide 23: Multi-Products
Multi-Products For personal use only Three product ranges entering profit phase Global Profit Concept Product Pilot ValidaWon Regulatory Revenue DistribuWon 2016 USCOM 1A ±✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Uscom BP+ ±✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ SpiroSonic ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Investment to Profit 26 IP shi\ing to profit
Slide 24: The Future: Value Cascade
The Future For personal use only Value Cascade Products Sales OperaWons OpportuniWes USCOM 1A New appointments Global opera,ons Share price growth Uscom BP+ Current distribu,on Increased products Dividend BP+Reporter Thor distribu,on Increased scale Transac,on SpiroSonic Comple,on of New distribu,on
Slide 25: Current Objectives
Uscom For personal use only Current Objec@ves • Maintain USCOM 1A 50+% growth • Deliver BP+, BP+Reporter, SpiroSonic and SpiroReporter to market • Complete products, regulatory and manufacturing • Con<nue discussions • Expand distribu<on with high reach partners • Develop specific applica<on partners
Slide 26: Operational risks
Uscom For personal use only Opera@onal risks • Global medical markets unpredictable • Product development/regulatory slower and more costly than expected • Distribution slow to achieve revenue goals and integrate new products • Capital for acquisitions, product development and production in advance
Slide 27: Right Sector - Health
Right Sector - Health For personal use only ASX 10 yr CAGR % pa 14.0 12.1 12.0 10.0 8.0 6.0 UCM sales growth % 4.0 3.5 2014 – 67% 2.0 0.0 0.1 0.0 2015 – 59% S&P 200 Financial NAB Materials BHP RMD Healthcare -2.0 Index (Mining) Index Index -2.4 -4.0 -4.5 -4.3 -6.0 • 1st Feb 2006 – 1st Feb 2016 • Exc
Slide 28: Right Time for Growth
Right Time for Growth For personal use only Revenue Growth % pa 60 50 40 Uscom 30 Resmed % 20 CSL Cochlear 10 0 2013 2014 2015 -10 26 Right company, right @me…..
Slide 29: Industry Comparators
Industry Comparators For personal use only 4 Reported and Predicted EBITDA 2 1.5 0 UCM ACG ADR BP ADR Ed -0.7 -1.1 -1.1 -1.1 -2 -1.81 -2.2 FY 15 AUD (m) -2.76 -4 FY 16* -4 FY 17* -5.15 -6 -6.1 -8 • Es@mates * • UCM -‐ Paterson’s, ACG -‐ Taylor Collison -10 ADR BP – BellPofer -10.1 ADR Ed -‐ Ediso
Slide 30: Share price starting to recognise revenue growth
ASX:UCM For personal use only Share price starWng to recognise revenue growth! UCM share price Revenue and Income $3,500,000 $3,100,000 $3,000,000 $2,500,000 $2,039,426 $2,000,000 $1,500,000 $1,377,716 $1,010,942 $1,000,000 $500,000 $0 2013 2014 2015 2016* Right company, right @me….. 9 * Estimate
Slide 31: Research – UCM 2016
Research – UCM 2016 For personal use only 9 BellDirect 6h May 2016 2016 performance…..
Slide 32: Research – UCM 2016
Research – UCM 2016 For personal use only 5th Oct 2015 5th Oct 2016 12mth Change 0.14c (14m) 0.42c (42m) +200% 12 month Projec@ons and price and cap value targets 9 Ben Kakoschke – 5th October, 2015
Slide 33: Uscom
Uscom For personal use only Value investment ✓ Experienced management ✓ Strong underlying business ✓ Strong growth phase ✓ Invested in growth ✓ Premium global markets ✓ Diversified and lifesaving technologies✓ Aggressive global growth strategy ✓ Two new product ranges for market in the next 12mths✓ R
Slide 34: Uscom
Uscom For personal use only “Has acquired global assets to ensure reliable revenue growth for investors for the coming decade.” 34 Uscom – Devices the experts use
Slide 35: Thank You
Uscom (UCM) – Global Medical Devices For personal use only Revenue Growth May 2016 Thank You Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO Uscom – Devices the experts us
Slide 36: USCOM 1A Competitive Advantage
USCOM 1A Competitive Advantage For personal use only Non- SV beat Method Manufacturer Technology Rel+Rep invasive Simple Cost Portable to beat USCOM 1A Uscom Doppler ✓ ✓ ✓ ✓ ✓ ✓ BioZ Samsung BioImpedance ✗ ✓ ✓ ✗ ✓ ✗ NiCOM Cheetah BioReactance ✗ ✓ ✓ ✗ ✓ ✗ Nexfin Bmeye APP ✗ ✓ ✓ ✓ ✓ ✗ CardioQ Deltex D
Slide 37: Testimonials
Testimonials For personal use only “This machine is saving lives, there are no two ways about it.” Professor Brendan Smith, Anesthe<st, Intensivist and Emergency Physician, N.S.W. Dept of Health, Australia “USCOM has changed the way I look at the cardiovascular status of my pa<ents. It’s part of the
Slide 38: BP+ Competitive Advantage
BP+ Competitive Advantage For personal use only Uscom BP+ TensioMed BPLab IEM Centron AtCor Australia Hungary Russia Germany UK Australia USD 3,500 USD 6,000 USD 7,000 USD 7,000 USD 6,300 USD 20,000 1 min 2 min 2 min 2 min 1 min 1 min Stand-alone ABP, needs computer ABP, needs computer ABP, needs co
Slide 39: Why?
Why ? For personal use only Independent research from Cambridge University, Weill Cornell, University of California, Wales Heart Ins@tute – BP+ = Four stars BP+ is on the interna@onal space sta@on 36 McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evid
Slide 40: SpiroSonic Competitive Advantage
SpiroSonic Competitive Advantage For personal use only Uscom Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD SpiroSonic Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD